Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 7707 results

  1. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development [GID-TA10685] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development [GID-TA10662] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development [GID-TA10665] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. eXroid for internal haemorrhoids

      Status ...

    Medical technologies guidance
    Topic selection

  5. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Respirasense

      Status ...

    Medical technologies guidance
    Topic selection

  7. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772

    Awaiting development [GID-TA11123] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548

    Awaiting development [GID-TA11128] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

    Technology appraisal guidance
    Topic selection

  12. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis TS ID 11773

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development [GID-TA10694] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development [GID-TA10715] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development